Merck to acquire biopharma company, OncoImmune
Merck will accelerate the development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.